Sensocure develops and manufactures biomedical sensors for healthcare, and aim to become the market leader in postoperative monitoring of internal organs.
The main product under development is IscAlert™, a CO2 sensor designed for the earliest possible detection of ischemia. Ischemia is a condition where the cells do not get enough oxygen to survive because of inadequate blood supply, and is the number 1 killer.
Early warning – Early action
If ischemia is detected early enough, the damage can be reversed and tissue saved. IscAlert™ detects ischemia at a very early stage by measuring the partial pressure of carbon dioxide in a body (a universal indicator of good blood supply).
Ischemia occurs in the form of myocardial infarction, stroke or
complications after operations and accidents, and is considered
the most common disease and cause of death in the
Sensocure AS develops biomedical
sensors for healthcare. The main product
under development is IscAlert™, a CO2
sensor designed for the earliest possible
detection of ischemia.
Press and public relations
We are proud to announce that Sensocure has earned position no. 482 in the 5th annual edition of the FT1000 Europe’s Fastest Growing Companies ranking. The rating is the result of a joint initiative by the Financial Times and Statista, which conducted months of...
Gjennom «Innovasjonsprosjekt i næringslivet», finansierer Norges Forskningsråd prosjekter med omfattende innhold av forsknings- og utviklingsaktiviteter, som skal gi et betydelig bidrag til fornyelse og økt verdiskaping for bedriftene som deltar i prosjektet, og for...
We have received funding from Innovation Norway for optimalization of our calibration method. In this project we will develop a one-stop-calibration method which is fast, robust and user friendly. The project period for project KALISC II will be from 2020-2023.